Characterization of the Melanoma-Specific Immune Response

Sponsored by University of California, Davis

Phase Quota
Phase 4

The aim of this study is to study T-cells. Blood will be collected and the samples will be used to generate T cell clones. Two separate blood draws will be required at the maximum.

Study Start Date: August 2007

Estimated Completion Date: November 2016

Specialties: Oncology: Dermatologic Oncology Dermatology: Dermatologic Oncology Physician Assistant: Hematology/Oncology


No interventions cited

Inclusion criteria

  • Biopsy diagnosis of malignant melanoma
  • Have had a biopsy diagnosis of malignant melanoma in the past

Exclusion criteria

  • Patients taking immunosuppressive medications

Study Locations And Contact Information

  • University of California Davis Department of Dermatology, Sacramento California
    Contact: Emanual Maverakis MD 916-734-6556

Feature this Clinical Trial

Get your trial in front of 1000s of physicians and patients.
Visit to find out how you can feature this clinical trial.